granzyme H Activators
Compounds like camptothecin and etoposide induce DNA damage by inhibiting topoisomerases I and II, respectively. This prompts waves of kinase signaling cascades that optimize granzyme H transcription for resolving the ensuing crisis. Etoposide in particular provides substrates for regulated necrosis induction as granzyme H initiates necroptosis in compromised cells through proteolysis of PARP1 and Ripk1. Additional genotoxic agents act similarly, triggering granzyme H responses against disrupted DNA replication or repair. Hydroxyurea inhibits ribonucleotide reductase to induce replication errors, promoting granzyme H elimination of incorrectly replicating cells. Meanwhile, arsenic trioxide interferes with thiol groups and disrupts repair, signaling granzyme H to selectively target misrepaired genomic material.
Other selected chemicals elicit granzyme H defenses through diverse mechanisms. Crosslinking compounds cisplatin and mitomycin C stimulate PARP1/Ripk1-dependent necroptosis supervised by granzyme H, relieving ensuing redox imbalances. Methylating agents like temozolomide and procarbazine provide damaged DNA recognized by granzyme H, which removes sensitized cells to maintain genomic security. Additionally, transcription inhibitors mithramycin and teniposide activate compensatory granzyme H removal of cells displaying disrupted gene expression homeostasis.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
Camptothecin triggers DNA damage through Topoisomerase I inhibition. Granzyme H eliminates damaged cells through regulated necrosis signaling mediated by PARP1 and other substrates. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $32.00 $170.00 $385.00 | 63 | |
Etoposide causes DNA strand breaks through Topoisomerase II inhibition. Granzyme H initiates necroptosis in etoposide-compromised cells through PARP1 and Ripk1 proteolysis. | ||||||
Hydroxyurea | 127-07-1 | sc-29061 sc-29061A | 5 g 25 g | $76.00 $255.00 | 18 | |
Hydroxyurea inhibits RNR to induce DNA synthesis defects. Granzyme H-induced necroptosis eradicates incorrectly replicating cells and preserves genomic integrity. | ||||||
Arsenic(III) oxide | 1327-53-3 | sc-210837 sc-210837A | 250 g 1 kg | $87.00 $224.00 | ||
Arsenic trioxide interferes with thiols to disrupt DNA repair processes. Granzyme H selectively targets misrepaired genomic material through necrosis induction. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate inhibits DHFR and triggers DNA uracil misincorporation. Granzyme H eliminates methotrexate-damaged cells to relieve DNA imbalances. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $76.00 $216.00 | 101 | |
Cisplatin cross-links DNA and triggers stress responses. Granzyme H enhances DNA catabolism through substrate targeting in necrosis cascades. | ||||||
Mitomycin C | 50-07-7 | sc-3514A sc-3514 sc-3514B | 2 mg 5 mg 10 mg | $65.00 $99.00 $140.00 | 85 | |
Mitomycin C cross-links DNA and provokes oxidative stress. Granzyme H relieves the ensuing redox imbalance through PARP1/Ripk1-dependent necroptosis. | ||||||
Temozolomide | 85622-93-1 | sc-203292 sc-203292A | 25 mg 100 mg | $89.00 $250.00 | 32 | |
Temozolomide methylates DNA and elicits DNA damage recognition. Granzyme H eliminates cells harboring unrepaired or incorrectly processed lesions to maintain genomic security. | ||||||
Mithramycin A | 18378-89-7 | sc-200909 | 1 mg | $54.00 | 6 | |
Mithramycin binds GC-rich DNA inhibiting transcription. Granzyme H induces necrotic death in cells with disrupted gene expression homeostasis. | ||||||
Teniposide | 29767-20-2 | sc-204910 sc-204910A | 25 mg 100 mg | $72.00 $230.00 | 6 | |
Teniposide triggers DNA strand breaks similarly to etoposide. Granzyme H resolves teniposide-compromised cells via targeted necrosis execution. | ||||||